Cart
sales@molnova.com
Aβ42-IN-2
CAS No. 1914989-80-2
Aβ42-IN-2( —— )
Catalog No. M37643 CAS No. 1914989-80-2
Aβ42-IN-2, a γ-secretase modulator with an IC50 of 6.5 nM for Αβ42, can be used for Alzheimer's disease research .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 89 | In Stock |
|
| 5MG | 82 | In Stock |
|
| 10MG | 129 | In Stock |
|
| 25MG | 215 | In Stock |
|
| 50MG | 299 | In Stock |
|
| 100MG | 412 | In Stock |
|
| 200MG | 570 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAβ42-IN-2
-
NoteResearch use only, not for human use.
-
Brief DescriptionAβ42-IN-2, a γ-secretase modulator with an IC50 of 6.5 nM for Αβ42, can be used for Alzheimer's disease research .
-
DescriptionAβ42-IN-2 is a γ-secretase modulator extracted from patent WO2016070107, compound example 36. Aβ42-IN-2 has an IC50 of 6.5 nM for Αβ42.Aβ42-IN-2 can be used for the research of Alzheimer's disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayNeuroscience
-
TargetGamma-secretase
-
RecptorGamma-secretase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1914989-80-2
-
Formula Weight430.5
-
Molecular FormulaC24H26N6O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 20 mg/mL (46.46 mM; Ultrasonic )
-
SMILESCOc1ccc(cc1)[C@H](C)Nc1nnc(cc1C)-c1ccc(c(OC)n1)-n1cnc(C)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Steven L. Wagner, et al. Potent gamma-secretase modulators. WO2016070107A1.
molnova catalog
related products
-
Brontictuzumab
Brontictuzumab (OMP 52M5) is a monoclonal antibody that targets Notch1 and inhibits activation of the pathway.
-
NGP555
NGP555 is a modulator of γ-secretase.
-
CB-103
CB-103 is a orally active inhibitor of notch signaling pathway, with anti-tumor activity. CB-103 has shown the ability to block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines, and?exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines.
